Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Precision Oncology Market 

5.1. COVID-19 Landscape: Precision Oncology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Precision Oncology Market, By Product

8.1. Precision Oncology Market, by Product, 2023-2032

8.1.1 Diagnostics

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Therapeutics0

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Precision Oncology Market, By Cancer Type

9.1. Precision Oncology Market, by Cancer Type, 2023-2032

9.1.1. Breast cancer

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Colorectal cancer

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Lung cancer

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Blood Cancer

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Prostate Cancer

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Precision Oncology Market, By Cancer Type 

10.1. Precision Oncology Market, by Cancer Type, 2023-2032

10.1.1. Pharmaceutical & Biotechnology Companies

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Hospitals & Diagnostic Laboratories

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Healthcare Data Companies

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Precision Oncology Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2020-2032)

11.1.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.1.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.2.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.3.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)

Chapter 12. Company Profiles

12.1. Thermo Fisher Scientific, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Invitae Corporation

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Illumina, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Myriad Genetics, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. AstraZeneca

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Rain Oncology Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Strata Oncology, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Repare Therapeutics

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Relay Therapeutics

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Exscientia

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms